Notable Mover: Cannabis Science Inc (CBIS) 2016 Q2 Sentiment Report

November 22, 2016 - By Ellis Scott   ·   0 Comments

Notable Mover: Cannabis Science Inc (CBIS)  2016 Q2 Sentiment Report

Sentiment for Cannabis Science Inc (CBIS)

Cannabis Science Inc (CBIS) institutional sentiment NaN in Q2 2016. Its in 2016Q1. The ratio [12345], as 1 active investment managers increased and started new positions, while 1 cut down and sold stock positions in Cannabis Science Inc. The active investment managers in our partner’s database now hold: 308,179 shares, up from 303,399 shares in 2016Q1. Also, the number of active investment managers holding Cannabis Science Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 0 Increased: 0 New Position: 1.

Cannabis Science, Inc. is engaged in medical marijuana research and development. The company has a market cap of $64.50 million. The Firm works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid pharmaceutical products. It currently has negative earnings. The Firm is involved in the creation of cannabis medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

About 45.29 million shares traded hands. Cannabis Science Inc (CBIS) has risen 70.00% since April 20, 2016 and is uptrending. It has outperformed by 65.44% the S&P500.

Donaldson Capital Management Llc holds 0% of its portfolio in Cannabis Science Inc for 49,780 shares. Frontier Investment Mgmt Co owns 20,000 shares or 0% of their US portfolio. Moreover, Massmutual Trust Co Fsb Adv has 0% invested in the company for 8,400 shares. The New York-based Neville Rodie & Shaw Inc has invested 0% in the stock. Stonebridge Capital Advisors Llc, a Minnesota-based fund reported 10,000 shares.#img1#

CBIS Company Profile

Cannabis Science, Inc., incorporated on May 4, 2007, is engaged in medical marijuana research and development. The Firm works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid pharmaceutical products. The Firm is involved in the creation of cannabis medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>